Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose ulinastatin in acute pancreatitis patients with risk factors for severe disease
CTR20264014Phase 3Active
- Sponsor
- Guangdong Tempu Biochemical Pharmaceutical
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ulinastatin in acute pancreatitis (AP), sponsored by Guangdong Tempu Biochemical Pharmaceutical. Started Oct 2026; status: active.
02
Drugs
ulinastatin
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on CTR20264014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264014.